Figitumumab has anti-tumor activity in Ewing's sarcoma

December 23, 2009

A preliminary study of the anticancer drug figitumumab has found that it has antitumour activity in Ewing's sarcoma—a cancer which affects mainly teenage boys. The results have led to the drug's progression to a Phase 2 trial in patients with Ewing's sarcoma, which has recently finished recruiting. These are the conclusions of an Article published Online First in the Lancet Oncology. The study is by Dr Johann S de Bono, The Institute for Cancer Research (ICR), Sutton, UK, and The Royal Marsden NHS Foundation Trust, Sutton, UK, and colleagues.

Ewing's sarcoma is a rare disease in which are found in the bone or soft tissue, most commonly the pelvis, femur, humerus, and ribs. It occurs most commonly it male teenagers with a male to female ratio of 1.6 to 1.

Data from preclinical studies have suggested that Ewing's sarcoma, and some other sarcoma subtypes, are dependent on the insulin-like growth factor signalling pathway. Figitumumab is a drug which targets the insulin-like growth-factor-1 receptor (IGF-1R). This phase I study was carried out to assess the effects of figitumumab in these sarcoma subtypes.

Between January, 2006, and August, 2008, patients with refractory, advanced sarcomas received figitumumab (20 mg/kg) in two groups within a phase 1 trial. The first cohort (15 patients) included patients with multiple sarcoma subtypes, age 18 years or older, and the second cohort (14 patients) consisted of patients with refractory Ewing's sarcoma, age nine years or older. The primary endpoint was to assess the safety and tolerability of figitumumab.

Of the 29 patients that were enrolled, 16 had Ewing's sarcoma, and the 29 received a total of 177 cycles of treatment (median 2, mean 6, range 1󈞄). In terms of adverse events, grade 3 deep venous thrombosis, grade 3 back pain, and grade 3 vomiting were each noted once in individual patients; one patient had grade 3 or 4 raised liver enzymes. The only other grade 4 adverse event was raised concentrations of uric acid, noted in one patient. A total of 28 patients were assessed for response; two patients, both with Ewing's sarcoma, had objective responses (one complete response and one partial response) and eight patients had disease stabilisation (six with Ewing's sarcoma, one with synovial sarcoma, and one with fibrosarcoma) lasting four months or longer.

The authors say: "Figitumumab is well tolerated and has antitumour activity in Ewing's sarcoma, warranting further investigation in this disease."

They conclude: "Our results show that figitumumab can be safe for both adult and paediatric sarcoma patients, and has single-agent antitumour activity in different sarcoma subtypes, including Ewing's sarcoma. Phase 2 studies of figitumumab and other anti-IGF-R agents in Ewing's sarcoma and other sarcoma subtypes are now completing accrual and rational combinations with other treatments are also being pursued."

In an accompanying Reflection and Reaction comment, Dr Jeffrey A Toretsky, Georgetown University, Washington DC, USA, and Dr Richard Gorlick, The Albert Einstein College of Medicine of Yeshiva University, The Children's Hospital at Montefiore, Bronx, NY, USA, say: "With several different companies developing IGF-1R inhibitors, there could be ample opportunity to optimise clinical benefit from IGF-1R blockade, although the development of these antibodies may be complicated. Five-drug chemotherapy is routine in the treatment of Ewing's , therefore improvement in outcome for these patients will likely require demonstration of the feasibility of combining the antibody with standard chemotherapy. Ultimately, a phase 3 randomised study investigating the benefit of this combination might provide the proof of activity that will achieve the IGF-1R-pathway promise."

Related Stories

Recommended for you

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.